Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin‐11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy

Abstract

From the payer's perspective, rhIL-11 cannot be considered a cost-saving clinical strategy compared with routine platelet transfusions for patients with severe chemotherapy-induced thrombocytopenia.